harold shlevin  galectin therapeutics inc  zoominfocom galectin therapeutics appoints harold h shlevin phd bioscience industry executive as chief operating officer  acorn management partners llc search email alerts facebook linkedin news  events home news  events client news galectin therapeutics appoints harold h shlevin phd bioscience industry executive as chief operating officer events client news galectin therapeutics appoints harold h shlevin phd bioscience industry executive as chief operating officer newton massbusiness wire galectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced the appointment of dr harold h shlevin as chief operating officer dr shlevin succeeds as of october   maureen foley who helped found the company and served as its coo since its inception and as its corporate secretary dr shlevin is a bioscience industry executive with  years of senior management experience in the development and commercialization of pharmaceuticals diagnostics and vaccines “dr shlevin will be a tremendous asset to galectin therapeutics as he brings a broad range of technical managerial and leadership experience in small medium and large pharmaceutical companies that includes a trackrecord of attracting capital competing successfully to negotiate partnering deals and developing and commercializing new pharmaceutical products” said peter g traber md president ceo and cmo of galectin “he has also has experience building effective leadership teams optimizing regulatory compliance and adherence to quality standards and aligning diverse functions in small companies global alliances and across corporate structures these qualities will be of great value to galectin therapeutics as we advance our candidates in liver fibrosis and cancer as we welcome dr shlevin i wish to thank ms foley for her long dedication and great contributions to the company” “i was attracted to galectin therapeutics because of its leadingedge applied science supported by a strong dedicated team of experienced individuals both of which are key criteria for success in this industry” said dr shlevin “i look forward to assisting galectin in developing new potential therapies for patients suffering from intractable liver and other diseases” dr shlevin most recently led georgia institute of technology’s advanced technology development center atdc as principle and manager of bioscience commercialization efforts where he served as a catalyst for new bioscience startup companies his leadership roles have included president and ceo of solvay pharmaceuticals where he oversaw the successful launch of the first topical testosterone gel product in the us cofounder of ciba vision ophthalmics a specialty ophthalmic drug company where he headed efforts leading to the approval of the first nonsteroidal agent for treatment of ocular inflammation and several other drug products founder president  ceo of tikvah therapeutics a company focused on clinical development of therapeutics for treatment of neurological diseases and vp and head of operations  commercial development for altea therapeutics corporation a clinicalstage drug delivery company with platform technology applicable to the transdermal delivery of biologics dr shlevin earned his ba from boston university and ms and phd in physiology from the university of rochester medical school he completed postdoctoral training in pharmacology at mayo clinic where he subsequently served as assistant professor of pharmacology  physiology he is a member of scientific and business societies including ieee licensing executives society am physiological society am society of pharmacology  experimental therapeutics and is an inventor on several issued and pending patents dr shlevin currently serves on the board of directors of cardiome pharma corp nasdaqcrme and neurop inc and as an advisor to clearside biomedical inc about galectin therapeutics galectin therapeutics nasdaq galt is developing promising carbohydratebased therapies for the treatment of fibrotic liver disease and cancer based on the companys unique understanding of galectin proteins key mediators of biologic function we are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development we are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer additional information is available at wwwgalectintherapeuticscom forwardlooking statements this press release contains in addition to historical information forwardlooking statements within the meaning of the private securities litigation reform act of  these statements relate to future events or future financial performance and use words such as may estimate could expect and others they are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements factors that could cause our actual performance to differ materially from those discussed in the forwardlooking statements include among others incurrence of operating losses since our inception uncertainty as to adequate financing of our operations extensive and costly regulatory oversight that could restrict or prevent product commercialization inability to achieve commercial product acceptance inability to protect our intellectual property dependence on strategic partnerships product competition and others stated in risk factors contained in our sec filings we cannot assure that we have identified all risks or that others may emerge which we do not anticipate you should not place undue reliance on forwardlooking statements although subsequent events may cause our views to change we disclaim any obligation to update forwardlooking statements galectin therapeutics inctom mcgauley acting chief financial officerirgalectintherapeuticscom source galectin therapeutics inc galt harold h shlevin insider trades for galectin therapeutics inc bulletin investor alert new york markets close in market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close galectin therapeutics inc nasdaq galt go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus galectin therapeutics inc countdown to close  quotes are delayed by  min jul    pm galt quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual harold h shlevin dr harold h shlevin is chief operating officer  secretary at galectin therapeutics inc independent director at cardiome pharma corp startup catalyst at atdc seed capital fund llc a member at the institute of electrical  electronics engineers inc a member at licensing executives society a member at the american physiological society and a member at american society for pharmacology  experimental therapeutic he is on the board of directors at cardiome pharma corp dr shlevin was previously employed as headbiosciences by advanced technology development center headbiosciences by georgia institute of technology headoperations  commercial development by altea development corp president  chief executive officer by tikvah therapeutics inc a director  global senior vice president by solvay pharmaceuticals inc chairman by unimed pharmaceuticals llc a director  global senior vice president by solvay pharmaceuticals sa and founder by ciba vision ophthalmics co he also served on the board at neurop inc and solvay draka inc he received his undergraduate degree from boston university a graduate degree from the university of rochester medical center and a doctorate degree from the university of rochester medical center transactions date shares transaction value          derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      acquisition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr marc rubin chairman dr peter g traber president ceo chief medical officer  director dr harold h shlevin chief operating officer  secretary mr jack w callicutt chief financial  accounting officer dr eliezer zomer executive vpmanufacturing  product development mr james c czirr director mr j rex horton executive directorregulatory affairs mr john f mauldin independent director dr gilbert frank amelio independent director mr arthur r greenberg independent director mr steven prelack independent director dr gil s omenn independent director mr kevin d freeman independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwall street isn’t ready for a point tumble in the dow industrials pis your amazon sale item truly discounted here’s how to find out ptesla earnings will model  live up to the hype pamerican airlines profit falls unit revenue gains poil logs its biggest weekly gain of the year pcan christopher nolan’s ‘dunkirk’ crack china’s market pwhy john mccain ignored trump plea and shot down obamacare repeal pus economy speeds up in second quarter after bumpy ride earlier in the year pwaters has testy exchange with mnuchin over trump financing ptreasury yields slide after secondquarter gdp data pinvestment chief who manages  billion sees big gains on the ‘frontier’ pthese companies spent over  billion buying back shares while their ceos were dumping them pthis fund strategist says there’s at least one way companies can survive amazon’s onslaught pweekend roundup amazon’s spending  surviving amazon  caterpillar’s comeback pwhat the proposed  cut in farm subsidies mean for your grocery bill phealthcare fund managers say a spike in drugs and devices will produce big returns pcorrectedgoodyear stock stumbles  after quarter ‘played out differently than we expected’ pwhat  million simulations tell us about president trump’s chances of achieving  economic growth ppeople still aren’t saving for retirement — and that’s part of why myra is shutting down pto be a better investor read more good novels loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  harold h shlevin phd executive profile  biography  bloomberg july    pm et biotechnology company overview of galectin therapeutics inc snapshotpeople  overviewboard memberscommittees executive profile harold h shlevin phdcoo  corporate secretary galectin therapeutics incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationshipsas of fiscal year  background dr harold h shlevin phd has been chief operating officer and corporate secretary of galectin therapeutics inc since october   dr shlevin was a principal and head of bioscience commercialization at advanced technology development center at georgia institute of technology he is a biosciences startup catalyst at advanced technology development center he is a year bioscienceindustry executive with broad senior management experience in medical devices  pharmaceuticals diagnostics and vaccines he has founded two startup companies dr shlevin served as vice president of product commercial development at altea therapeutics corporation since may  dr shlevin served as the president and chief executive officer of tikvah therapeutics inc since june  he served as the chief executive officer and president of abbott products inc also known as solvay pharmaceuticals inc from june  to january  he served as senior vice president of business development and scientific affairs of abbott products inc since august  his past industry experience includes senior executive positions at bausch  lomb pharmaceuticals gd searle and co cibageigy pharmaceuticals now novartis and ciba vision and was a founder of ciba vision opthalmics dr shlevin served as the chairman of unimed pharmaceuticals inc he serves as a member of the board of solvay draka he serves as a member of the scientific advisory board at clearside biomedical inc he serves as a director of unimed pharmaceuticals inc dr shlevin serves on the board of directors of the american foundation for suicide prevention the board of advisors of morehouse school of medicine and board of directors for the georgia biomedical partnershiphe served as a director at cardiome pharma corp since october   until june   he served as a director of tikvah therapeutics inc and abbott products inc he served as an assistant professor of pharmacology and physiology at the mayo graduate school of medicine mayo foundation and mayo clinic dr shlevin served as a director of the pharmaceutical research  manufacturers of america national pharmaceutical council he is a member of the american society of pharmacology and experimental therapeutics the american physiological society the biophysical society the drug information association and the licensing executives society he holds postdoctoral degrees in pharmacology and physiology from the mayo graduate school of medicine mayo foundation and mayo clinic dr shlevin earned a doctorate and masters degree from university of rochester medical school and a bachelors degree from the boston universityread full background corporate headquarters  peachtree industrial boulevardnorcross georgia united statesphone fax  board members memberships directorunimed pharmaceuticals llc education bachelors degree boston universitydoctorate university of rochester medical centermasters degree university of rochester medical centermasters degree mayo graduate school other affiliations advanced technology development centerunimed pharmaceuticals llccardiome pharma corpboston universityabbvie products llcaltea therapeutics corporationuniversity of rochester medical centermayo graduate schooltikvah therapeutics incclearside biomedical inc annual compensation salarybonustotal annual compensation stocks options all other compensationexercisable optionsunexercisable optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact galectin therapeutics inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close harold h shlevin pres ceo tikvah therapeutics inc a publisher of business information since         search business search executive   advanced search   sign in    hints email profiles and emails of executives   harold shlevin   pres ceo   harold shlevins email  please login   company name  tikvah therapeutics inc   company website  httpwwwtikvahtherapeuticscom   company address   fifth st nwste  atlanta gaunited states   harold shlevins profile  pres ceo   harold shlevins biography  harold has served as tikvah therapeutics’ president and ceo since its establishment in june  under his leadership product licenses have been executed the business concept and plan were established and the nucleus of the management team has been built tikvah therapeutics inc an atlanta ga pharmaceutical enterprise is focused on latestage development of compounds with strong intellectual property protection and significant market potential tikvah therapeutics inc primary development focus is on the novel application of existing therapeutic entities where clinical proof of concept is already wellestablished and its commercial focus is in the specialty areas of cns  psychiatry and neurology this strategy is designed to minimize the risk of rd while maximizing the commercial potential of its product assetsprior to tikvah therapeutics harold held various positions of increasing leadership responsibility at solvay pharmaceuticals he most recent held the position of global senior vice president of solvay pharmaceuticals sa reporting directly to the head of the worldwide pharmaceuticals business this role including global pl responsibility functioned to assure the company effectively managed its regulated activities worldwide he was a member of the solvay pharmaceuticals sa board of directors responsible for the worldwide pharmaceutical business and also remained a member of the board of directors of the us pharmaceuticals business shlevin joined solvay pharmaceuticals as senior vice president of business development and scientific affairs in august  and served as president and chief executive officer of solvay pharmaceuticals inc from june  to january  he was also a member of the management committee an officer of the corporation chairman of the board of its independently owned and operated subsidiary unimed pharmaceuticals inc and a member of the board of solvay draka a specialty plastic company with interest in medical device applications under harold’s leadership as ceo solvay pharmaceuticals inc experienced a period of record growth in revenue and profits these achievements were underpinned by aggressive acquisitions and research and development importantly a longstanding adverse regulatory situation in the usa which blocked product approvals by fda was resolved without fines or consent decrees harold initiated activities and then successfully led the efforts of solvay pharmaceuticals inc to apply for a us federal grant for development and production of new cellbased technologies for influenza vaccine resulting in the department of health and human services award to solvay pharmaceuticalsus for us million in may harold has over twentyfive years of diverse healthcare businessrelated experience involving virtually every aspect of the pharmaceutical business from research and development through commercial operations his past industry experience includes leadership roles at gd searle and co cibageigy corporation and he was a founder of ciba vision ophthalmics after earning a bachelor’s degree from boston university harold earned a master’s and doctorate from university of rochester medical school he holds postdoctoral degrees in pharmacology and physiology from the mayo graduate school of medicine mayo foundation and mayo clinic where he also served as assistant professor of pharmacology and physiology he served on the board of directors of the pharmaceutical research and manufacturers association of america and the national pharmaceutical council and as an advisor to nanovici inc a nanotechnology oriented startup company focused on oncology he is a member of the american society of pharmacology and experimental therapeutics the american physiological society the biophysical society the drug information association and the licensing executives society he currently serves on the board of directors of the american foundation for suicide prevention the board of advisors of morehouse school of medicine the board of directors of cardiome pharma corporation nasdq crme board of directors for the georgia biomedical partnership and vice chair of its executive committee   harold shlevins colleagues  name title email jack callicutt cfo vp please login lou barbato vp  research development chief medical officer please login garratt ponder vp  pharmaceutical development please login sandy weinberg vp  regulatory affairs quality assurance please login john graham dir please login  other executive with same profile             home    about us    product information     subscription    list builder     executive list     email lists     contact us    site map    browse directory        walkerss research  a publisher of business information since  all rights reserved galectin therapeutics appoints harold h shlevin phd bioscience industry executive as chief operating officer  business wire galectin therapeutics appoints harold h shlevin phd bioscience industry executive as chief operating officer august    am eastern daylight time newton massbusiness wiregalectin therapeutics inc nasdaq galt the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer today announced the appointment of dr harold h shlevin as chief operating officer dr shlevin succeeds as of october   maureen foley who helped found the company and served as its coo since its inception and as its corporate secretary dr shlevin is a bioscience industry executive with  years of senior management experience in the development and commercialization of pharmaceuticals diagnostics and vaccines “dr shlevin will be a tremendous asset to galectin therapeutics as he brings a broad range of technical managerial and leadership experience in small medium and large pharmaceutical companies that includes a trackrecord of attracting capital competing successfully to negotiate partnering deals and developing and commercializing new pharmaceutical products” said peter g traber md president ceo and cmo of galectin “he has also has experience building effective leadership teams optimizing regulatory compliance and adherence to quality standards and aligning diverse functions in small companies global alliances and across corporate structures these qualities will be of great value to galectin therapeutics as we advance our candidates in liver fibrosis and cancer as we welcome dr shlevin i wish to thank ms foley for her long dedication and great contributions to the company” “i was attracted to galectin therapeutics because of its leadingedge applied science supported by a strong dedicated team of experienced individuals both of which are key criteria for success in this industry” said dr shlevin “i look forward to assisting galectin in developing new potential therapies for patients suffering from intractable liver and other diseases” dr shlevin most recently led georgia institute of technology’s advanced technology development center atdc as principle and manager of bioscience commercialization efforts where he served as a catalyst for new bioscience startup companies his leadership roles have included president and ceo of solvay pharmaceuticals where he oversaw the successful launch of the first topical testosterone gel product in the us cofounder of ciba vision ophthalmics a specialty ophthalmic drug company where he headed efforts leading to the approval of the first nonsteroidal agent for treatment of ocular inflammation and several other drug products founder president  ceo of tikvah therapeutics a company focused on clinical development of therapeutics for treatment of neurological diseases and vp and head of operations  commercial development for altea therapeutics corporation a clinicalstage drug delivery company with platform technology applicable to the transdermal delivery of biologics dr shlevin earned his ba from boston university and ms and phd in physiology from the university of rochester medical school he completed postdoctoral training in pharmacology at mayo clinic where he subsequently served as assistant professor of pharmacology  physiology he is a member of scientific and business societies including ieee licensing executives society am physiological society am society of pharmacology  experimental therapeutics and is an inventor on several issued and pending patents dr shlevin currently serves on the board of directors of cardiome pharma corp nasdaqcrme and neurop inc and as an advisor to clearside biomedical inc about galectin therapeutics galectin therapeutics nasdaq galt is developing promising carbohydratebased therapies for the treatment of fibrotic liver disease and cancer based on the companys unique understanding of galectin proteins key mediators of biologic function we are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development we are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer additional information is available at wwwgalectintherapeuticscom forwardlooking statements this press release contains in addition to historical information forwardlooking statements within the meaning of the private securities litigation reform act of  these statements relate to future events or future financial performance and use words such as may estimate could expect and others they are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements factors that could cause our actual performance to differ materially from those discussed in the forwardlooking statements include among others incurrence of operating losses since our inception uncertainty as to adequate financing of our operations extensive and costly regulatory oversight that could restrict or prevent product commercialization inability to achieve commercial product acceptance inability to protect our intellectual property dependence on strategic partnerships product competition and others stated in risk factors contained in our sec filings we cannot assure that we have identified all risks or that others may emerge which we do not anticipate you should not place undue reliance on forwardlooking statements although subsequent events may cause our views to change we disclaim any obligation to update forwardlooking statements contacts galectin therapeutics inctom mcgauley acting chief financial officerirgalectintherapeuticscom release summary galectin therapeutics inc nasdaq galt appoints dr harold h shlevin as chief operating officer succeeding maureen foley as of october   contacts galectin therapeutics inctom mcgauley acting chief financial officerirgalectintherapeuticscom search advanced news search advanced news search log in sign up harold h shlevin  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors harold h shlevin check out list of companies and businesses related to harold h shlevin find out harold h shlevin address and contact details view other people related to harold h shlevin  coworkers colleagues companions etc address co galectin therapeutics inc  peachtree industrial blvd ste  norcross  ga companies related to harold h shlevin cikcompany namepositioncompany addressgalectin therapeutics incchief operating officer  peachtree industrial boulevard suite  norcross  harold h shlevin on the web persons related to harold h shlevin  galectin therapeutics incnamepositioncityx capital management llcnicevillex fund lp owner nicevillex fund lp owner nicevillegilbert f ameliodirector gilbert f ameliodirector newtongilbert f ameliodirector norcrossgilbert f ameliodirector norcrossgilbert f ameliodirector newtonklyosov anatolenewtonsqueglia anthonynewtongreenberg arthurnewtongreenberg arthurnorcrossedgar benjosefdirector newtonjack w callicuttchief financial officer atlantajack w callicuttchief financial officer norcrossmildred s christiandirector newtonmildred s christiandirector newtonmildred s christiandirector newtondale h conawaydirector newtondale h conawaydirector newtondale h conawaydirector newtonjames c czirrdirector sandpointjames c czirrexecutive chairman sandpointjames c czirrexecutive chairman newtonjames c czirrexecutive chairman newtonjames c czirrexecutive chairman newtonjames c czirrnorcrossjames c czirrexecutive chairman norcrosszomer eliezernewtonhenry jemil esberdirector west boylstonhenry jemil esberdirector newtonburton c firteldirector newtonburton c firteldirector newtonburton c firteldirector newtonmaureen foleychief operating officer newtonmaureen foleychief operating officer newtonmaureen foleychief operating officer newtonkevin d freemandirector newtonkevin d freemandirector norcrossamelio gilbertnewtonamelio gilbertnorcrossomenn gilbertnorcrossjames theophile gourzisnewtonjames theophile gourzisdirector newtonarthur greenbergdirector newtonarthur greenbergdirector newtonarthur greenbergdirector norcrossshlevin haroldnorcrosscallicutt jacknorcrossczirr jamesnewtonczirr jamesnorcrossrome jerald wells avenuemauldin johnnorcrossfreeman kevinnorcrosscarl laurence luederschief financial officer newtoncarl laurence luederschief financial officer newtonrubin marcnorcrossrod d martindirector newtonrod d martindirector newtonrod d martindirector nicevillerod d martindirector newtonrod d martindirector norcrossrod d martindirector newtonrod d martindirector norcrossjohn f mauldindirector newtonjohn f mauldindirector newtonjohn f mauldindirector norcrossfoley maureennewtonthomas mcgauleynewtonthomas mcgauleychief financial officer newtonthomas mcgauleychief financial officer newtonsydney colin neilldirector newtonsydney colin neilldirector newtongilbert s omenndirector thousand oaksgilbert s omennnorcrosstraber peternorcrosstraber peternewtondavid plattchairman  ceo newtondavid plattchairman  ceo newtondavid plattchairman  ceo newtonsteven prelackdirector newtonsteven prelackdirector newtonsteven prelackdirector newtonsteven prelackdirector norcrosssteven prelackdirector norcrossherman paul presslerdirector newtonherman paul presslerdirector newtonherman paul presslerdirector norcrossmartin rodnewtonjerald k romenewtonjerald k romedirector newtonjerald k romedirector newtonjerald k romedirector newtonjerald k romedirector norcrossmarc rubindirector englewoodmarc rubinnewtonmarc rubindirector norcrossneill snewtonharold h shlevinchief operating officer newtonharold h shlevinchief operating officer norcrossharold h shlevinchief operating officer norcrossdavid h smithdirector norwalkdavid h smithdirector newtondavid h smithdirector newtonanthony don squeglianewtonprelack stevennewtonprelack stevennorcrosszucconi theodorenewtonzuconni theodorenorcrosspeter g traberpresident  ceo houstonpeter g traberdirector newtonpeter g traberdirector houstonpeter g traberceo and president newtonpeter g traberpresident and ceo norcrosspeter g traberpresident  ceo norcrossrichard e uihleinpleasant prairieeliezer zomerex vp mfg  product dev newtoneliezer zomerex vp mfg  product dev newtontheodore daniel zucconidirector newtontheodore daniel zucconidirector newton harold shlevin biosciences industry executive joins atdc as a manager and catalyst innovationdriven economic developmentwhile creating the nextmenuclosehome about us about economic impact connecting with gt resources annual reports leadership staff directory atlanta office regional offices careers programs commercialization venturelab gtips innovation corps entrepreneurship atdc innovation centers economic development lab science technology and innovation policy business services gamep gtpac mbda setaac health it extension professional education contracting academy people leadership staff directory regional offices success stories news careers contact us harold shlevin biosciences industry executive joins atdc as a manager and catalyst december   by eiadmin leave a comment harold shlevin harold h shlevin phd a year biosciencesindustry executive and researcher has joined georgia tech’s advanced technology development center atdc as manager of atdcbiosciences he will serve as a startup catalyst advising new bioscience companies within the atdc in his new atdc position shlevin will evaluate and guide new and emerging bioscience enterprises that are based on georgia tech research innovations as well as others across georgia he will work with nina sawczuk a veteran biosciences entrepreneur who is now atdc’s assistant director for biosciences responsible for supporting the commercialization of bioscience innovation throughout the state “there is and will continue to be a willingness among venture capitalists and others to invest in innovation that helps people live healthier lives” shlevin said “georgia tech is wellpositioned to supply that innovation because of the high quality and diversity of multidisciplinary science here and because there is a willingness among the faculty to see their science realized in some type of application” from  shlevin held positions of increasing responsibility at solvay pharmaceuticals inc these posts included global senior vice president of solvay pharmaceuticalssa president and ceo of solvay pharmaceuticals inc and senior vice president of business development and scientific affairs shlevin’s combination of academic and business experience offers a strong background for his work as an atdc biosciences manager and catalyst said stephen fleming vice provost at georgia tech’s enterprise innovation institute atdc’s parent organization “harold’s decision to join atdc is good news for georgia tech and georgia” fleming said “i’m confident he will help us expand georgia’s bioscience industry which plays a highly important economic role in the state” shlevin earned a bachelor’s degree in biology from boston university and a master’s and a doctorate in physiology from university of rochester medical school his doctoral research focused on electrophysiology and biophysics of excitable cells he holds a postdoctoral certificate in pharmacology and physiology from the mayo graduate school of medicine the mayo clinic and the university of minnesota he also served as an assistant professor of pharmacology and physiology at mayo medical school and the university of minnesota shlevin has an extensive list of both academic and business publications he holds several global patents covering a variety of medical devices drugs and electromechanical products and has six patents pending he has been active in the community serving on the board of advisers of morehouse school of medicine and the psychiatry department of emory university school of medicine he has been an adviser and director of several healthcarerelated software companies and a nanotechnologyoriented startup company focused on oncology he currently serves on the board of directors of the georgia bio organization and is vice chair of its executive committee he is also on the board of directors of cardiome pharma corp shlevin believes georgia is well positioned to expand its already extensive list of bioscience companies he praised georgia tech’s close connections with emory university and its school of medicine georgia tech’s collaboration with emory has produced the wallace h coulter department of biomedical engineering which is ranked among the nation’s top biomedical engineering schools “the ability to reach out to people who are practicing clinical medicine and receive their input is a huge benefit” he said “it is those people who can best help define the potential application of a given technology and that in turn reduces market risk and supports the funding of ventures based on that technology” atdc is a startup accelerator that helps georgia technology entrepreneurs launch and build successful companies founded in  atdc has helped create millions of dollars in tax revenues by graduating more than  companies which together have raised more than a billion dollars in outside financing recently atdc expanded its mission by merging with georgia tech’s venturelab and with the georgia sbir assistance program the change enables atdc to greatly extend its reach to serve more technology companies along multiple growth paths and at all stages of development atdc has opened its membership to all technology entrepreneurs in georgia from those at the earliest conception stage to the wellestablished venturefundable companies atdc is part of the enterprise innovation institute ei at georgia tech which helps georgia enterprises improve their competitiveness through the application of science technology and innovation atdc currently has three facilities two at georgia tech’s main campus in atlanta and one at georgia tech’s satellite campus in savannah research news  publications office georgia institute of technology  fifth street nw suite  atlanta georgia  usa media relations contact john toon  email udehcetagnullnootj writer rick robinson categories entrepreneurs front page news tags atdc entrepreneurs speak your mind cancel reply name  email  website resources search ei resources enterprise innovation institute  th street nw atlanta ga  phone  georgia tech resources offices  departments news center campus calendar special events greenbuzz institute communications visitor resources campus visits directions to campus visitor parking information gtvisitor wireless network information georgia tech global learning center georgia tech hotel  conference center barnes  noble at georgia tech ferst center for the arts robert c williams paper museum harold shlevin biosciences industry executive joins atdc as a manager and catalyst innovationdriven economic developmentwhile creating the nextmenuclosehome about us about economic impact connecting with gt resources annual reports leadership staff directory atlanta office regional offices careers programs commercialization venturelab gtips innovation corps entrepreneurship atdc innovation centers economic development lab science technology and innovation policy business services gamep gtpac mbda setaac health it extension professional education contracting academy people leadership staff directory regional offices success stories news careers contact us harold shlevin biosciences industry executive joins atdc as a manager and catalyst december   by eiadmin leave a comment harold shlevin harold h shlevin phd a year biosciencesindustry executive and researcher has joined georgia tech’s advanced technology development center atdc as manager of atdcbiosciences he will serve as a startup catalyst advising new bioscience companies within the atdc in his new atdc position shlevin will evaluate and guide new and emerging bioscience enterprises that are based on georgia tech research innovations as well as others across georgia he will work with nina sawczuk a veteran biosciences entrepreneur who is now atdc’s assistant director for biosciences responsible for supporting the commercialization of bioscience innovation throughout the state “there is and will continue to be a willingness among venture capitalists and others to invest in innovation that helps people live healthier lives” shlevin said “georgia tech is wellpositioned to supply that innovation because of the high quality and diversity of multidisciplinary science here and because there is a willingness among the faculty to see their science realized in some type of application” from  shlevin held positions of increasing responsibility at solvay pharmaceuticals inc these posts included global senior vice president of solvay pharmaceuticalssa president and ceo of solvay pharmaceuticals inc and senior vice president of business development and scientific affairs shlevin’s combination of academic and business experience offers a strong background for his work as an atdc biosciences manager and catalyst said stephen fleming vice provost at georgia tech’s enterprise innovation institute atdc’s parent organization “harold’s decision to join atdc is good news for georgia tech and georgia” fleming said “i’m confident he will help us expand georgia’s bioscience industry which plays a highly important economic role in the state” shlevin earned a bachelor’s degree in biology from boston university and a master’s and a doctorate in physiology from university of rochester medical school his doctoral research focused on electrophysiology and biophysics of excitable cells he holds a postdoctoral certificate in pharmacology and physiology from the mayo graduate school of medicine the mayo clinic and the university of minnesota he also served as an assistant professor of pharmacology and physiology at mayo medical school and the university of minnesota shlevin has an extensive list of both academic and business publications he holds several global patents covering a variety of medical devices drugs and electromechanical products and has six patents pending he has been active in the community serving on the board of advisers of morehouse school of medicine and the psychiatry department of emory university school of medicine he has been an adviser and director of several healthcarerelated software companies and a nanotechnologyoriented startup company focused on oncology he currently serves on the board of directors of the georgia bio organization and is vice chair of its executive committee he is also on the board of directors of cardiome pharma corp shlevin believes georgia is well positioned to expand its already extensive list of bioscience companies he praised georgia tech’s close connections with emory university and its school of medicine georgia tech’s collaboration with emory has produced the wallace h coulter department of biomedical engineering which is ranked among the nation’s top biomedical engineering schools “the ability to reach out to people who are practicing clinical medicine and receive their input is a huge benefit” he said “it is those people who can best help define the potential application of a given technology and that in turn reduces market risk and supports the funding of ventures based on that technology” atdc is a startup accelerator that helps georgia technology entrepreneurs launch and build successful companies founded in  atdc has helped create millions of dollars in tax revenues by graduating more than  companies which together have raised more than a billion dollars in outside financing recently atdc expanded its mission by merging with georgia tech’s venturelab and with the georgia sbir assistance program the change enables atdc to greatly extend its reach to serve more technology companies along multiple growth paths and at all stages of development atdc has opened its membership to all technology entrepreneurs in georgia from those at the earliest conception stage to the wellestablished venturefundable companies atdc is part of the enterprise innovation institute ei at georgia tech which helps georgia enterprises improve their competitiveness through the application of science technology and innovation atdc currently has three facilities two at georgia tech’s main campus in atlanta and one at georgia tech’s satellite campus in savannah research news  publications office georgia institute of technology  fifth street nw suite  atlanta georgia  usa media relations contact john toon  email udehcetagnullnootj writer rick robinson categories entrepreneurs front page news tags atdc entrepreneurs speak your mind cancel reply name  email  website resources search ei resources enterprise innovation institute  th street nw atlanta ga  phone  georgia tech resources offices  departments news center campus calendar special events greenbuzz institute communications visitor resources campus visits directions to campus visitor parking information gtvisitor wireless network information georgia tech global learning center georgia tech hotel  conference center barnes  noble at georgia tech ferst center for the arts robert c williams paper museum microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft